News Focus
News Focus
Followers 59
Posts 7595
Boards Moderated 0
Alias Born 10/20/2014

Re: Number sleven post# 419186

Friday, 12/15/2023 9:34:10 PM

Friday, December 15, 2023 9:34:10 PM

Post# of 448144
Number sleven, Yes, I am aware. What I would like to have is some indication that management
is looking into this as a priority. There are many studies that are conducted in cancer trials that use
multiple drugs looking for any hint of a synergy. Pure EPA, in the right dosage, seems to affect most
any medical issue in a positive manner. Too me it seems obvious that pure EPA should be studied
as a potential adjunct drug, especially for cancer as it may end up that EPA may help with many
(if not all) various types of cancer. Just this week I heard about a "failed" cancer drug that was
used with Keytruda. There are literally hundreds of trials that are using Keytruda. Would be
encouraging to find at least one that used EPA as an adjunct drug in at least one arm of a
clinical trial of Keytruda.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News